中国肺癌杂志最新文献

{"title":"[Research Progress on the Mechanism of Gut Microbiota \u2029Influencing Lung Cancer Brain Metastasis via the Brain-gut Axis].","authors":"Dan Li, Liang Chen, Pengqiang Lv, Quanshi Yang, Jianxin Yang, Deming An, Yu Yu, Guoming Gao","doi":"10.3779/j.issn.1009-3419.2025.101.20","DOIUrl":"10.3779/j.issn.1009-3419.2025.101.20","url":null,"abstract":"<p><p>Lung cancer, one of the leading causes of cancer-related deaths worldwide, severely influences patients' quality of life and prognosis due to its complication of brain metastasis (primarily involving the brain parenchyma). While traditional treatments such as surgery, radiotherapy, and chemotherapy have demonstrated efficacy in clinical practice, their application remains limited due to toxicity and patient tolerance issues. Emerging targeted therapies and immunotherapies, which exhibit significant efficacy with fewer side effects, still face challenges including partial drug resistance and genetic mutations. In recent years, research on the association between gut microbiota and lung cancer brain metastasis has gained prominence. Its mechanism of action may influence the progression of brain metastasis through multidimensional interactions via the brain-gut axis, involving neuroendocrine and immune pathways. This review examines specific mechanisms by which gut microbiota modulate lung cancer brain metastasis through immune regulation, endocrine-metabolic regulation, and neurotransmitter control via the brain-gut axis, as well as therapeutic and traditional medicine research on regulating gut microbiota in lung cancer brain metastasis. It aims to provide theoretical support and identify potential clinical therapeutic targets for the prevention and treatment of lung cancer brain metastasis.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 11","pages":"849-856"},"PeriodicalIF":0.0,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12883950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Fecal Microbiota Transplantation: A Promising Avenue for Lung Cancer Therapy].","authors":"Xiuwen Hong, Yaqian Deng, Jiao Feng, Cui Bao, Yuanyuan Zhang, Nan Gao, Hong Shen","doi":"10.3779/j.issn.1009-3419.2025.101.21","DOIUrl":"10.3779/j.issn.1009-3419.2025.101.21","url":null,"abstract":"<p><p>As lung cancer treatment continues to advance, mainstream approaches such as surgery, radiotherapy, chemotherapy, neoadjuvant therapy, targeted therapy and immunotherapy have become widely adopted in clinical practice. However, the efficacy of these methods is still limited and they are associated with significant side effects. In recent years, the pivotal role of the gut microbiota in tumor immune regulation has become increasingly recognized, with its potential impact on tumor immunotherapy emerging as a novel therapeutic focus in lung cancer management. Against this backdrop, fecal microbiota transplantation (FMT) has been proposed as a potential immunomodulatory strategy. It enhances host immune responses and improves the tumor immune microenvironment by regulating the gut microbiota. This paper provides a systematic review of the latest research advances in FMT for lung cancer treatment. Focusing on the relationship between gut microbiota and lung cancer, the therapeutic mechanisms of FMT and clinical application studies, it provides a comprehensive exploration of the challenges and prospects for the use of FMT in lung cancer therapy.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 11","pages":"841-848"},"PeriodicalIF":0.0,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12883947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case of Refractory Pulmonary Enteric Adenocarcinoma with EGFR Sensitive Mutation].","authors":"Xinyi Wang, Ning Mu, Feng'e Li, Mei Liu, Yue Xu, Shengnan Wu, Huan Lv, Chunhua Ma","doi":"10.3779/j.issn.1009-3419.2025.102.44","DOIUrl":"10.3779/j.issn.1009-3419.2025.102.44","url":null,"abstract":"<p><p>Pulmonary enteric adenocarcinoma (PEAC) is a distinct subtype of non-small cell lung cancer (NSCLC) whose histomorphology and immunophenotype closely resemble those of metastatic colorectal adenocarcinoma; its pathogenesis and standard treatment strategies have yet to be clearly established. Here, we reported a case of PEAC harboring epidermal growth factor receptor (EGFR) exon 19 deletion mutation with high programmed cell death ligand 1 (PD-L1) expression. The patient showed no meaningful response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs), including the first-generation (Icotinib), the second-generation (Afatinib) and the third-generation (Aumolertinib). Trophoblast cell surface antigen 2-antibody-drug conjugate (TROP2-ADC) and immune checkpoint inhibitors (ICIs) combined with Bevacizumab also resulted in limited efficacy. Based on the clinical features and treatment response of this case, we reviewed the published literature about the pathological characteristics, mutational landscape, and current therapeutic approaches for PEAC, with a particular focus on the therapeutic challenges and future research directions for EGFR-mutant PEAC, aiming to provide insights for clinical practice and further studies.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 11","pages":"882-886"},"PeriodicalIF":0.0,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12883945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Risk Factors, Molecular Mechanisms, and Multimodal Early Warning Strategies \u2029for Immune Checkpoint Inhibitor-associated Pneumonitis in Lung Cancer].","authors":"Jurong Zhan, Xiudi Chen, Na Li","doi":"10.3779/j.issn.1009-3419.2025.101.19","DOIUrl":"10.3779/j.issn.1009-3419.2025.101.19","url":null,"abstract":"<p><p>In recent years, immune checkpoint inhibitors (ICIs), as a revolutionary therapeutic approach in oncology, have demonstrated remarkable clinical efficacy across various malignant tumors. With the widespread clinical application of ICIs, their associated toxicities have emerged as a critical issue that urgently requires resolution in the field of cancer immunotherapy. ICIs-associated pneumonitis (CIP) specifically refers to immune-related adverse events (irAEs) of the lung induced by ICIs therapy, the underlying pathogenesis of which remains incompletely elucidated. As a rare yet severe complication of ICIs treatment, and CIP is characterized by insidious onset, rapid progression, poor prognosis, and high mortality rate, with highly heterogeneous clinical manifestations and radiological features. Due to the lack of specific biomarkers and objective diagnostic indicators, the early identification and diagnosis of CIP present significant clinical challenges. By reviewing previous literature and studies, this paper summarizes recent advances in understanding the clinical manifestations, risk factors, potential molecular mechanisms, biomarkers, and early warning systems of CIP in patients receiving immunotherapy for lung cancer. The aim of this article is to provide a reference for the clinical management of CIP and offer a theoretical basis for establishing an early screening and precision diagnosis and treatment system for this condition.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 11","pages":"857-865"},"PeriodicalIF":0.0,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12890442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Influence and Mechanism of Immunophenotyping on the Efficacy \u2029of Neoadjuvant Therapy in Non-small Cell Lung Cancer].","authors":"Li Wu, Liying Yang, Miaoqing Zhao, Jian Sun, Fanghan Cao, Qianhui Chen, Xiaorong Sun, Ligang Xing","doi":"10.3779/j.issn.1009-3419.2025.106.31","DOIUrl":"10.3779/j.issn.1009-3419.2025.106.31","url":null,"abstract":"<p><strong>Background: </strong>The low response rate to immunotherapy can be partially attributed to tumor immune escape mechanisms arising from the heterogeneous tumor microenvironment. This study aims to determine the impact of inflammatory non-small cell lung cancer (NSCLC) on the efficacy of neoadjuvant immunotherapy combined with chemotherapy at the histological level, and to investigate the predictive value of specific CD8+ and CD4+ T cell numbers, as well as spatial interactions, in treatment response.</p><p><strong>Methods: </strong>A retrospective study included 43 patients with NSCLC who underwent neoadjuvant immunotherapy combined with chemotherapy at Shandong Cancer Hospital from January 2021 to June 2023. Preoperative biopsy specimens were collected and subjected to multiplex immunofluorescence staining [CD8/programmed cell death protein 1 (PD-1)/T cell immunoglobulin and mucin-domain containing protein 3 (TIM-3)/CD4/ forkhead box protein 3 (FoxP3)/cytokeratin (CK)/4',6-diamidino-2-phenylindole (DAPI)]. InForm software was used to perform tissue segmentation (epithelial and stromal regions) and quantify the density and spatial proximity of tumor cells, CD8+ T cells and their subsets (cytotoxic, pre-exhausted and exhausted), as well as CD4+ T cells and their subsets (conventional and regulatory). NSCLC was classified into three subtypes based on the relative infiltration levels of CD8+ T cells in both the epithelial and stromal compartments: inflamed (both compartments>10/1000), excluded (epithelial compartment<10/1000 and stromal compartment>10/1000), and desert (both compartments<10/1000). The Kolmogorov-Smirnov test, Fisher's exact test, Mann-Whitney U test and Logistic regression were used to identify factors associated with major pathological response (MPR).</p><p><strong>Results: </strong>Inflamed, excluded, and desert NSCLC accounted for 65.1%, 27.9% and 7.0%, respectively. Compared with patients with non-inflamed NSCLC, those with inflamed NSCLC exhibit a higher MPR rate (71.4% vs 33.3%, P=0.016). Both univariate and multivariate Logistic regression analyses confirmed that the inflamed subtype is an independent protective factor against the acquisition of MPR in NSCLC patients (OR=0.20, 95%CI: 0.05-0.74, P=0.020; adjusted OR=0.17, 95%CI: 0.03-0.80, P=0.030). Analysis of the spatial distance between CD8+ and CD4+ T cells within the epithelial regions of inflamed NSCLC revealed that the effective density of cytotoxic CD8+ T cells within a 30 μm radius of regulatory CD4+ T cells was lower in the MPR group than in the non-MPR group (0.00 vs 0.33, P=0.037).</p><p><strong>Conclusions: </strong>Patients with inflamed NSCLC demonstrate superior efficacy when receiving neoadjuvant immunotherapy combined with chemotherapy. This may be due to reduced proximity between regulatory CD4+ T cells and cytotoxic CD8+ T cells.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 11","pages":"807-817"},"PeriodicalIF":0.0,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12883946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research Progress on Interleukin-6 in Screening and Prognosis of Patients \u2029with Non-small Cell Lung Cancer].","authors":"Dongyang Xu, Chenxiao Qiao, Xiaoying Zhang, Qingchao Kong, Xiang Ji","doi":"10.3779/j.issn.1009-3419.2025.101.18","DOIUrl":"10.3779/j.issn.1009-3419.2025.101.18","url":null,"abstract":"<p><p>Non-small cell lung cancer (NSCLC), the predominant histological subtype of lung cancer, mandates precise screening and accurate prognostic assessment to guide therapeutic strategies and improve patient survival. The initiation and progression of NSCLC are intimately linked to inflammatory responses. Interleukin-6 (IL-6), a pivotal inflammatory mediator, critically modulates the tumor microenvironment, immune evasion, tumor progression, and therapy resistance in NSCLC. Recent evidence indicates that IL-6 not only participates in the biological behavior of NSCLC but also holds promise as a potential biomarker for early detection and prognostication. This review summarizes the role of IL-6 in NSCLC screening, treatment-related adverse events, and its utility in the management of NSCLC-associated comorbidities.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 10","pages":"787-797"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12782942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145918725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Application of Explainable Deep Learning in Differentiating Benign from Malignant \u2029Pulmonary Space-occupying Lesions and Classifying Pathological Subtypes of Lung Cancer].","authors":"Haoran Li, Yuanyuan Wang, Yang Wang, Huihui He, Junya Li, Yanning Su, Fanrui Kong, Xiangli Liu, Liuhui Cheng, Ya Li","doi":"10.3779/j.issn.1009-3419.2025.102.36","DOIUrl":"10.3779/j.issn.1009-3419.2025.102.36","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;The discrimination between benign and malignant pulmonary space-occupying lesions and the classification of pathological subtypes of lung cancer are critical for clinical decision-making. However, conventional methods often suffer from insufficient utilization of multi-source clinical data and poor interpretability of deep learning models. This study investigates the performance of interpretable deep learning algorithms in diagnosing benign versus malignant pulmonary space-occupying lesions and classifying pathological subtypes of lung cancer, using a hybrid architecture based on Tab-Transformer-designed for tabular data and Residual Multi-Layer Perceptron (ResMLP), referred to as TT-ResMLP.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Data including radiological characteristics, medical history, and laboratory findings from 345 patients with pathologically confirmed pulmonary space-occupying lesions were collected. The dataset was randomly split into a development set and a test set at an 8:2 ratio. Stable features were selected using the Spearman correlation test and the Least Absolute Shrinkage and Selection Operator (LASSO). The Synthetic Minority Over-sampling Technique (SMOTE) was employed to balance the samples, and 10-fold cross-validation was used to enhance model generalizability. Models were constructed using the Tab-Transformer algorithm, the ResMLP algorithm, and the TT-ResMLP hybrid. Model performance was evaluated using receiver operating characteristic (ROC) curves, the area under the curve (AUC), accuracy, specificity, sensitivity, and micro-averaged ROC (micro-ROC). SHapley Additive exPlanations (SHAP) analysis was performed based on the optimal model.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;In the benign vs malignant diagnosis task, all three models performed well. The Tab-Transformer model demonstrated the best performance on the test set, followed by TT-ResMLP and ResMLP. SHAP analysis of the top-performing Tab-Transformer model revealed that the feature importance ranking was: age, pleural indentation, thrombin time, mean density, and ground-glass opacity. Pleural indentation contributed substantially to malignant diagnosis, and its contribution was further enhanced with increasing age and decreasing thrombin time. In the lung cancer subtype classification task, all three models exhibited excellent performance, with the TT-ResMLP hybrid showing the best overall performance. SHAP analysis further revealed that the Lung Imaging Reporting and Data System (Lung-RADS) category held high importance across all three pathological subtypes. Male gender was positively associated with the prediction of squamous cell carcinoma. Neuron-specific enolase (NSE) played a significant role in predicting small cell carcinoma. For adenocarcinoma, the diagnostic probability was positively correlated with the Lung-RADS category, a relationship more pronounced at lower prothrombin time (PT) values. In contrast, a negative correlation was","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 10","pages":"738-750"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12782943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145918688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expert Consensus on the Clinical Application of Sodium Cantharidinate and Vitamin B6 Injection].","authors":"","doi":"10.3779/j.issn.1009-3419.2025.102.37","DOIUrl":"10.3779/j.issn.1009-3419.2025.102.37","url":null,"abstract":"<p><p>Cancer prevention and control in China face severe challenges. Although targeted therapy and immunotherapy have made remarkable progress, chemotherapy remains a cornerstone of comprehensive cancer treatment, and its toxic side effects pose a significant challenge in clinical practice. As a compound formulation exhibiting both antitumor and toxicity-reducing effects, Sodium cantharidinate and vitamin B6 injection has been utilized in clinical practice in China for over two decades. However, standardized guidelines for its application remain lacking in routine clinical use. To address this gap, the Lung Cancer Specialty Committee of Chinese Elderly Health Care Association organized a panel of experts to develop this consensus document, drawing on current evidence-based data and accumulated clinical experience. This consensus provides a systematic elaboration of the preparation's pharmacological mechanisms and pharmacokinetic profiles, and offers specific recommendations for its clinical application across various malignancies, including lung cancer and hepatocellular carcinoma. The primary objective of this consensus is to establish standardized guidance for clinicians regarding the appropriate use of Sodium cantharidinate and vitamin B6 injection, thereby promoting its rational application and ultimately enhancing treatment efficacy and quality of life for cancer patients.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 10","pages":"727-737"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12788493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145918738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Integrative Analysis of Multi-source Public Databases to Screen Core Genes \u2029for Constructing A Prognostic Risk Model in Lung Adenocarcinoma].","authors":"Chengmeng Wang, Lu Zhang, Yu Zhang, Yu Wang, Meng Wang","doi":"10.3779/j.issn.1009-3419.2025.102.38","DOIUrl":"10.3779/j.issn.1009-3419.2025.102.38","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Tyrosine kinase inhibitors (TKIs) resistance poses a significant challenge in the targeted therapy of lung adenocarcinoma (LUAD), highlighting the need to identify key molecular markers associated with both drug resistance and prognosis to guide precision treatment. This study aimed to elucidate the molecular mechanisms underlying TKIs resistance in LUAD, identify core differentially expressed genes (DEGs), clarify the relationships between different gene clusters and patient survival/drug response, and construct and validate a prognostic risk model for LUAD, thereby providing a foundation for precision therapy and prognostic assessment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Multiple LUAD-related datasets, including GSE162045 and GSE114647, were integrated. Core overlapping DEGs were identified using Venn diagrams, and a gene correlation network was constructed. Consensus clustering was applied for sample grouping, combined with t-SNE dimensionality reduction to visually validate clustering stability and distinctness. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Set Enrichment Analysis (GSEA) were performed to explore the functional enrichment of DEGs. The 50% maximal inhibitory concentration (IC50) values of 12 drugs were compared across clusters to evaluate differences in drug sensitivity. Prognosis-related core genes were selected via LASSO regression to construct a risk model, whose performance was subsequently validated in the GSE31210 cohort using Sankey diagrams, Kaplan-Meier survival curves, and receiver operating characteristic (ROC) curves. Expression differences of core genes among clusters and between risk groups were analyzed, and Kaplan-Meier curves were plotted to assess the association between individual gene expression and survival. The expression of PLEK2 in LUAD tissues was analyzed based on multiple datasets (GSE19804, GSE19188, GSE44077, GSE30219), and its protein level in epidermal growth factor receptor (EGFR)-TKIs-resistant LUAD cell lines was detected by Western blot.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Twelve core DEGs (e.g., HMGA1, PLEK2) were identified. When the cluster number (K) was set to 2, samples were stably divided into Cluster A and Cluster B. The expression of 10 core genes was significantly different between the two clusters (P&lt;0.0001), and the patients in Cluster A exhibited significantly better overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) compared to those in Cluster B. Notable differences were observed in the mutation profiles of high-frequency genes such as TP53, KRAS and EGFR between the clusters. KEGG enrichment analysis revealed that the DEGs were primarily enriched in pathways such as \"Cell cycle\" and \"Neuroactive ligand-receptor interaction\". GSEA indicated significant associations with gene sets related to the malignant progression of tumors. Drug sensitivity analysis demonstrated significant differences in IC50 values for ","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 10","pages":"751-760"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12782933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145918651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research Advances on the Autophagy and Ferroptosis \u2029in the Development and Treatment of Lung Cancer].","authors":"Chengqi Jiang, Xueping Cui, Li Zheng, Chengkun Deng, Ruoshan Huang, Bo Hou, Junfeng Wang","doi":"10.3779/j.issn.1009-3419.2025.102.41","DOIUrl":"10.3779/j.issn.1009-3419.2025.102.41","url":null,"abstract":"<p><p>Lung cancer remains a life-threatening malignancy with complex pathogenesis. This paper provides a systematic review of autophagy and ferroptosis-related signaling pathways, key regulatory factors, and their associated mechanisms, including the nuclear receptor coactivator 4 (NCOA4)-mediated ferritin autophagy-ferroptosis axis, mitochondrial autophagy, lipid droplet autophagy, circadian autophagy, chaperone-mediated autophagy, etc.. The review elucidates the roles of the tumor microenvironment and non-coding RNAs in autophagy-ferroptosis processes in lung cancer. Furthermore, it explores the potential of modern drugs and active components from traditional Chinese medicine to improve lung cancer outcomes by targeting autophagy and ferroptosis, proposing that targeting their interactive pathways could offer novel therapeutic strategies for lung cancer.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 10","pages":"777-786"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12782934/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145918691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}